USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Angiogen, Inc.
Address:
Angiogen, Inc.
4050 Sorrento Valley Blvd, Ste O
San Diego, CA 92121 0142
Phone:
(858) 457-3707
URL:
N/A
EIN:
364301841
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $200,000.00 4
STTR Phase I $135,887.00 1

Award List:

VASCULARIZATION OF MANY SOLID TUMORS OCCURS IN VIVO AS A CONSEQUENCE OF THE VECTORIAL GROWTH OF HOST CAPILLARY ENDOTHELIAL CELLS ALONG A CONCENTRATION GRADIENT OF TUMOR- PRODUCED, DIFFUSIBLE ANGIOGENESIS FACTOR(S).

Award Year / Program / Phase:
1986 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Allan h fenselau , PRINCIPAL INVESTIGATOR
Abstract:
Vascularization of many solid tumors occurs in vivo as a consequence of the vectorial growth of host capillary endothelial cells along a concentration gradient of tumor- produced, diffusible angiogenesis factor(s). the identification of one of these factors as "angiogenic copper" raises the… More

THE PROPOSED STUDY TARGETS THE WELL-VASCULARIZED AND REFRACTORY CLASS OF CENTRAL NERVOUS SYSTEM (CNS) TUMORS FOR THE DEVELOPMENT OF NOVEL METHODS FOR DETECTING THE PRESENCE AND QUANTITATING AMOUNTS OF SPECIFIC TUMOR-PRODUCED ANGIO- GENESIS FACTORS (AF).

Award Year / Program / Phase:
1986 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Allan fenselau , PRINCIPAL INVESTIGATOR
Abstract:
The proposed study targets the well-vascularized and refractory class of central nervous system (cns) tumors for the development of novel methods for detecting the presence and quantitating amounts of specific tumor-produced angio- genesis factors (af). cell homogenates and condition media from cell… More

RETINOPATHY TREATMENT: HEPARIN-TARGETED ANTIANGIOGENESIS

Award Year / Program / Phase:
1987 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Allan fenselau phd
Abstract:
Proliferative retinopathy, or ocular disorders characterized by abnormal retinal neovascularization, presents a serious challenge in ophthalmology. conventionaltreatments-laser photocoagulation and vitrectomy-retard but do not necessarily abolish neovascularization and, in the process, produce… More

EFFECTS OF ANGIOGENESIS FACTORS ON SKIN FLAP SURVIVAL

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
In spite of the common use of skin grafts and skin flaps in plastic and reconstructive surgery, serious complications still arise. the complete or partial necrosis that can occur in surgical flaps or grafts is due to prolonged tissueischemia that compromises tissue blood flow. prompt… More